



RayBiotech, Inc.

3607 Parkway Lane suite 200
Norcross, GA 30092
Tel: 770-729-2992, 1-888-494-8555
Fax: 770-206-2393
Website: www.raybiotech.com
Email: info@raybiotech.com

Certificate of Analysis and DataSheet

Rabbit anti Mouse Apo A1

Catalog No.
MD-19-0039

Species
Mouse

Isotype:
N/A

Description:

Rabbit Antibody Anti-Mouse Apolipoprotein A1 (Apo A1)

Specificity:

Species specific: Extremely low recognition of human Apo A1

Host Animal:

New Zealand Rabbit

Immunogen:

Purified Mouse Apolipoprotein A1 from mouse plasma high-density lipoprotein

Format:

Neat, Liquid

Purification:

Not applicable
Product is 0.22µm filtered.

Concentration:

Not determined
Titer: 1:40 (RID)

Buffer:

Not applicable

Preservative:

0.025% Sodium azide

Storage:

Upon receipt, aliquot and store (up to 1 year) at -70°C. Avoid multiple freeze/thaw cycles.

**The products are furnished for LABORATORY RESEARCH USE ONLY.
Not for diagnostic or therapeutic use.**



RayBiotech, Inc.

3607 Parkway Lane suite 200
Norcross, GA 30092
Tel: 770-729-2992, 1-888-494-8555
Fax: 770-206-2393
Website: www.raybiotech.com
Email: info@raybiotech.com

Application:

Suitable for use in Radial immunodiffusion assay, immuno double-diffusion, rocket IEP and immunoblotting. Each laboratory should determine an optimum working titer for use in its particular application. Other applications have not been tested but use in such assays should not necessarily be excluded.

References:

- The references listed below are for research purposes only.
- Basso, F., et al., (2007), "Hepatic ABCG5/G8 Overexpression Reduces apoB-lipoproteins and Atherosclerosis When Cholesterol Absorption is Inhibited", *J. Lipid Res.*, 48:114-126
- Brown, R.J., et al., (2004), "Severe Hypoalphalipoproteinemia in Mice Expressing Human Hepatic Lipase Deficient in Binding to Heparan Sulfate Proteoglycan", *The Journal of Biological Chemistry*, 279(41): 42403-42409
- Conde-Knape, K., et al., (2002), "Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase", *J. Lipid Res.*, 43: 2136-2145
- Fagan, A.M., et al., (2004), "ApoAI Deficiency Results in Marked Reduction in Plasma Cholesterol But no Alterations in Amyloid-beta Pathology in a Mouse Model of Alzheimer's Disease-Like Cerebral Amyloidosis", *American Journal of Pathology*, 165(4): 1413-1422
- Frank, P.G., et al., (2004), "Genetic Ablation of Caveolin-1 Confers Protection Against Atherosclerosis", *Arterioscler Thromb. Vasc. Biol.*, 24: 98-105
- Gruen, M.L., et al., (2005), "Persistence of high density lipoprotein particles in obese mice lacking apolipoprotein A-I", *J. Lipid Res.*, 46: 2007-2014
- Navab, M., et al., (2003), "Oral Synthetic Phospholipid (DMPC) Raises High-Density Lipoprotein Cholesterol Levels, Improves High-Density Lipoprotein Function, and Markedly Reduces Atherosclerosis in Apolipoprotein E-Null Mice", *Circulation*, 108: 1735-1739
- Dansky, H.M., et al., (1999), "Genetic background determines the extent of Atherosclerosis in Apo E-Deficient Mice", *Arterioscler. Thromb. Vasc. Biol.*, 19: 1960-1968
- Hayhurst, G.P., et al., (2001), "Hepatocyte Nuclear Factor 4 alpha (Nuclear Receptor 2A1) is essential for maintenance of Hepatic Gene Expression and Lipid Homeostasis", *Molecular and Cellular Biology*, 21(4): 1393-1403
- Vaisman, B.L., et al., (2001), "ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice", *J. Clin. Invest.*, 108: 303-309

**The products are furnished for LABORATORY RESEARCH USE ONLY.
Not for diagnostic or therapeutic use.**